Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 57 | 7,762 | 33% |
| 2020 | 48 | 6,700 | 36% |
| 2021 | 51 | 7,066 | 39% |
| 2022 | 47 | 7,466 | 41% |
| 2023 | 52 | 7,905 | 43% |
| 2024 | 55 | 8,709 | 45% |
| 2025 from claims | – | 9,925 9,108–10,500 | 46% |
| 2026 forecast | – | 10,437 9,183–12,044 | 46% |
| 2027 forecast | – | 10,954 9,365–13,054 | 47% |
| 2028 forecast | – | 11,496 9,592–14,076 | 47% |
| 2029 forecast | – | 12,064 9,853–15,129 | 47% |
| 2030 forecast | – | 12,658 10,141–16,222 | 48% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 62% of the cases CMS names in New Jersey; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 16% inpatient hospital, 7% hospital outpatient, 0% surgery center, 77% office. The share outside the hospital has moved +34 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.5 | 60% | 16,300 in 2030+4.6%/yr |
| Pennsylvania | 34 | 4,796−11%/yr | −11%/yr | 3.3 | 15% | 4,870 in 2030+0.3%/yr |
| Massachusetts | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.5 | 43% | 4,060 in 2030+3.1%/yr |
| Connecticut | 14 | 1,650−9%/yr | −9%/yr | 4.7 | 71% | 1,560 in 2030−1%/yr |
| New Hampshire | 5 | 534−11%/yr | −11%/yr | 2.3 | 0% | 1,240 in 2030+15%/yr |
| Rhode Island | 4 | 346−12%/yr | −12%/yr | 3.6 | 54% | 380 in 2030+1.5%/yr |
| Maine | 1 | 250−14%/yr | −14%/yr | 1.5 | 0% | 260 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 58 | 7,071−13%/yr | −13%/yr | 7.01.3× | 70% | 7,590 in 2030+1.2%/yr |
| Superficial venous ablation | 70 | 4,906−2.3%/yr | −2.3%/yr | 4.51.4× | 97% | 6,260 in 2030+4.1%/yr |
| Thrombectomy, IVC filters & venous stents | 25 | 1,782+1%/yr | +1%/yr | 1.71.3× | 28% | 1,690 in 2030−0.8%/yr |
| Carotid revascularization | 26 | 1,073−1.9%/yr | −1.9%/yr | 1.01.0× | 0% | 1,090 in 2030+0.2%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 400−7.7%/yr | −7.7%/yr | 0.40.9× | 0% | 360 in 2030−1.6%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Boston Scientific leads with 30% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 12 companies reported engagement with New Jersey’s surgeons worth $52K in consulting, speaking, meals and travel tied to these products, about $942 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.